Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 9/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24233062 | 0.81 | NPC1 (0.59) | SMN1; SMN2PDGFRBKDRRAB9ANPC1 | |
| SCHEMBL29373917 | 0.81 | NPC1 (0.59) | SMN1; SMN2PDGFRBKDRRAB9ANPC1 | |
| SCHEMBL423204 | 0.80 | PDGFRB (0.61) | TP53SMN1; SMN2MAPTPDGFRBKDR | |
| SCHEMBL441291 | 0.79 | CA1 (0.55) | TP53PDGFRBKDRMEN1KMT2A | |
| SCHEMBL443510 | 0.78 | MDM2 (0.56) | SMN1; SMN2MAPTPDGFRBKDRRAB9A | |
| SCHEMBL3592057 | 0.78 | RAB9A (0.63) | PDGFRBKDRRAB9ANPC1MEN1 | |
| SCHEMBL2730940 | 0.77 | CA1 (0.53) | TP53SMN1; SMN2MAPTPDGFRBKDR | |
| SCHEMBL442236 | 0.77 | RAB9A (0.65) | SMN1; SMN2MAPTPDGFRBKDRRAB9A | |
| SCHEMBL422455 | 0.76 | LPL (0.61) | SMN1; SMN2MAPTPDGFRBKDRRAB9A | |
| SCHEMBL441557 | 0.76 | RAB9A (0.62) | TP53SMN1; SMN2MAPTPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | GBA1 3789/4885TP53 1024/4885SMN1; SMN2 2902/4885 |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | GBA1 3789/4885TP53 1024/4885SMN1; SMN2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.